Integra LifeSciences Holdings revenue growth has been varied year-over-year.

What is IART's revenue growth rate?

Historical revenue data is available for Integra LifeSciences Holdings to analyze growth trends.

How fast is IART earnings growing?

Earnings growth data is available for Integra LifeSciences Holdings analysis.

What is IART's profit margin?

Profit margin data is available for Integra LifeSciences Holdings.

IART Revenue & Earnings Growth Analysis 2026 - Is Integra LifeSciences Holdings Growing?

Growth Summary

Integra LifeSciences Holdings (IART) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Medical Devices industry.

Over the past 4 years, Integra LifeSciences Holdings has achieved a revenue compound annual growth rate (CAGR) of 42.7%.

Latest Revenue

$1.61B

Net Income

$-6944000.00

5-Year Revenue CAGR

42.7%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Integra LifeSciences Holdings

The chart above illustrates Integra LifeSciences Holdings's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Integra LifeSciences Holdings's business.

Profit Margin Trends

How efficiently Integra LifeSciences Holdings converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Integra LifeSciences Holdings retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$2.34

Current: $-0.09

EPS Estimate 2027

$2.56

9.5% expected growth

Price Target

$15.57

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Integra LifeSciences Holdings to continue growing earnings in the coming year. The consensus analyst rating is 2.9167 based on 12 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Integra LifeSciences Holdings (IART) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 42.7% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Integra LifeSciences Holdings's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.